9 Newly Approved Novel Drugs
It's been a busy year for the FDA.
6. KISQALI (ribociclib), Novartis
Indications: A kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Dosage: 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment.